Atomoxetine (StratteraŽ) | Print |  Email

Trial status:  Completed

Trial name: Atomoxetine and Huntington's Disease

FDA phase:  Phase II

Sponsor: Eli Lilly and Company

Trial results:  The study showed that there was no positive effect from atomoxetine on daily activities such as attention and focus, thinking ability, and muscle movements.

Location: University of Iowa

 
< Prev   Next >

To comment on this article or contact HDDW for any other reason, please email us.

© 2007 HDDW. All Rights Reserved.